FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.
Page 6 of 40
Sep 11, 2026The White House said the money is meant to help Americans facing higher costs, but the eligible population is narrow and appears concentrated in states using the federal marketplace. The proposal also arrives just before the midterm elections and after Republicans declined to extend enhanced ACA premiums that expired this year.
Sep 11, 2026The survey indicates shortages are still forcing leading cancer centers to ration inventory, avoid waste and use minimum suggested dosing to keep patients on therapy. Two-thirds of centers also said shortages delay care because they must seek prior authorization from insurers again when treatment plans change.
Sep 10, 2026Biohaven said the partial clinical hold affects enrollment in two late-stage focal epilepsy studies, while dosing can continue in participants already randomized. The company said the relevance of the nonclinical metabolite findings to humans is uncertain and expects additional nonclinical data in the coming weeks.
Sep 10, 2026Administration officials have linked AI adoption to a $50 billion rural health transformation fund and framed the technology as a way to lower delivery costs. Rural health leaders and health AI experts told STAT that current tools can reduce documentation burden and support workflows, but may not offset the financial pressure already hitting at-risk systems.
Sep 10, 2026ARPA-H said it will fund development of AI systems intended to help treat heart failure, including assessing symptoms, prescribing drugs and ordering lab tests. The program pairs a funding push with an explicit goal of producing Food and Drug Administration-authorized devices, making it as much a regulatory test as a technical one.
Sep 9, 2026The FDA’s two main product-review centers now have permanent leaders, with Michael Davis taking CDER and Karim Mikhail taking CBER after serving in acting roles since mid-May. The move comes as President Trump’s nominee for commissioner, Heidi Overton, still awaits a Senate confirmation process, leaving the agency in a partial but more defined leadership reset.
Sep 8, 2026Etcamah is cleared for patients with HR+/HER2- advanced breast cancer whose ESR1 mutations are detected during aromatase inhibitor and CDK4/6 inhibitor therapy, and it is intended for use with a CDK4/6 blocker. The approval arrived even after an independent panel voted 6-3 against backing the drug on the basis of the phase 3 SERENA-6 study.
Pallone’s letters target C2C Innovative Solutions, Commence, Dane Street, EdiPhy Advisors, National Medical Reviews and ProPeer Resources. His inquiry centers on whether the IDR process is operating as Congress intended and whether arbitration outcomes are contributing to higher consumer costs and premiums.
Sep 5, 2026The new recommendations cover how clinicians should evaluate tactical athletes with cardiovascular disease or at risk of developing it in light of their professional demands. The guidance extends sports cardiology principles into service roles where sudden exertion, environmental extremes and stress can change the consequences of even common risk factors.
Sep 4, 2026According to STAT, Clancy sought help from multiple providers in the four months before killing her three children and attempting to kill herself, but those clinicians did not communicate with one another. The report frames the case as an example of a broader structural problem in privately insured U.S. care.
Sep 4, 2026The TEMPO pilot gives digital health companies including Cadence and Limbic a route to put products in patients’ hands before formal authorization. For the Food and Drug Administration, the program creates a real-world testing ground for regulating care-influencing generative AI tools while supporting a payment experiment in chronic disease management.
Sep 3, 2026The program is aimed at replacing a centralized manufacturing model with faster, more accessible production for personalized RNA therapies. Early work will focus on cancer, rare genetic conditions and chronic diseases, with several biotech and academic teams assigned distinct manufacturing and quality-control roles.
Machine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.